|
|
|
Free
hCG-b
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ß-hCG (ng/ml) |
Absorbance (450 nm) |
|
0 |
0.061 |
|
2.5 |
0.296 |
|
5.0 |
0.498 |
|
10.0 |
0.929 |
|
25.0 |
1.711 |
|
50.0 |
2.613 |
14 STANDARDIZATION
For
intact hCG, 1 ng is approximately equivalent to 15 mIU (WHO, 1st IRP 75/537).
For free β-hCG subunit, since there is no WHO standardization, we
tested the free β-hCG against
hCG’s ELISA kit, and found 1 ng of free β-hCG equals to 0.1 mIU in terms
of hCG immunological activity.
15 EXPECTED VALUES AND INDICATIONS FOR QUANTITATIVE FREE ß-hCG ASSAY
The
following information is cited from reference no.12:
1
.
hCG and Free β-hCG
Subunit Levels in Normal Pregnancy
A
logarithmic increase in the serum concentration of hCG was observed from 5-8
weeks of gestation (2,600 ng/ml to 33,000 ng/ml) as defined by last menstrual
period; thereafter, hCG values decreased. Similarly, free β-hCG
levels increased rapidly to reach maximum levels (~60 ng/ml) at 8-9 weeks of
pregnancy, followed by a gradual decline during the next 11-12 weeks of
gestation.
At
5 weeks of gestation, the ratio of free β-hCG
to intact hCG is approximately 1.0 % (w/w). Thereafter, this ratio remains
remarkably constant over 22 weeks of gestation (~ 0.5 % w/w).
Free
α
and free β-subunits
and hCG levels were measured in five patients with untreated gestational
choriocarcinoma. The concentrations in serum are shown in the following table.
|
Patient Number |
hCG (ng/ml) |
Free α-hCG (ng/ml) |
Free
β-hCG (ng/ml) |
|
1 |
210,000 |
112 |
8,000 |
|
2 |
22,195 |
20 |
1,300 |
|
3 |
6,840 |
1 |
232 |
|
4 |
36,000 |
44 |
3,900 |
|
5 |
4,200 |
2 |
350 |
The
levels of free α-hCG were low, ranging from 1-112 ng/ml, whereas hCG levels ranged from
4,200 to 210,000 ng/ml (1 ng ≈ 15 mIU). In contrast, free β-hCG
concentrations were found to be markedly elevated in choriocarcinoma.
3.
Ectopic Production of hCG and Free Subunits by Nontrophoblastic Tumors
The
following table shows results obtained in various tumors and healthy and benign
disease controls:
Measurement
of hCG, α-hCG,
and β-hCG
serum levels
in nontrophoblastic tumors, benign
disease, and healthy controls
|
Tumor type |
No.
of samples |
hCG (ng/ml) |
α-hCG (ng/ml) |
β-hCG (ng/ml) |
|
Cervix |
20 |
0 |
1
(1.6)a |
1
(0.65) |
| Corpus
uterus |
20 |
0 |
0 |
0 |
| Gastric |
20 |
0 |
0 |
1
(1.5) |
| Pancreatic |
20 |
0 |
1
(16.0) |
2
(0.8, 3.1) |
| Colon |
20 |
0 |
0 |
0 |
| Lung |
20 |
0 |
1
(90.0) |
1
(0.7) |
| Ovarian |
20 |
0 |
1
(1.8) |
0 |
| Prostate |
20 |
0 |
1
(1.6) |
0 |
| Other
digestive tract tumor |
18 |
0 |
0 |
0 |
| Total
[%] |
178 |
0 |
5
[3] |
5
[3] |
| Benign
disease controls |
61 |
0 |
1
(1.6) |
0 |
| Healthy
controls |
50 |
0 |
0 |
0 |
| Total
[%] |
11 |
0 |
1
[1] |
0 |
a
The number in parentheses represents the measured value in ng/ml.
The
cut-off values for positive results are 1.5 ng/ml for hCG and α-hCG
and 0.4 ng/ml for β-hCG.
When
compared with healthy control values, all nontrophoblastic cancer patients had
hCG concentration within the normal range (~ 0.9 ng/ml). Free subunits were
elevated in 10 of 178 patients. It is noteworthy that α-hCG
levels in two patients (pancreatic and lung tumors) were relatively high (16 and
90 ng/ml, respectively), whereas the maximum concentration of free β-hCG
was only 3.1 ng/ml (pancreatic tumor).
16 PERFORMANCE CHARACTERISTICS
16.1 Specificity
Cross-reactivity
|
Antigens |
Conc. |
Equivalent hCG |
% Cross-Reactivity |
|
TSH |
1,000
ng/ml |
0.0
ng/ml |
0.00 |
|
FSH |
5,000 ng/ml |
0.0
ng/ml |
0.00 |
|
Prolactin |
1,000
ng/ml |
0.68
ng/ml |
0.07 |
|
LH |
1,000
ng/ml |
4.88
ng/ml |
0.49 |
|
Α-hCG |
5,000
ng/ml |
1.25
ng/ml |
0.03 |
|
Intact
hCG |
1,000 ng/ml |
7.24
ng/ml |
0.72 |
16.2 Sensitivity
The
minimal detectable concentration of ß-hCG in this assay is estimated to be 0.25
ng/ml.
17 REFERENCES
1.
Engall, E.,
Methods in Enzymology, volume 70, Van Vunakis, H. and Langone, J.J. (eds.),
Academic Press, new York, 419-492 (1980).
2.
Uotila M., Ripsöajto,
E. and Engvall E., J.Immunol. Metods, 42, 11-15 (2981)
3.
Brizot, ML, Jauniaux E. Mckie AT, Farzaneh F and Niclaides KH. Hum.
Reprod. 1995; 10; 2506-9.
4.
Forest JC,
Masse J, Rousseau F, Moutquin JM, Brideau NA and Belanger M. Clin. Biochem.
1995; 28:443-9.
5.
Breimer L.
ann.Clin.Biocehm 1995:32:233.
6.
Loncar
K,Barnabei VM, and Larsen JW Jr. Obstet. Gynecol. Surv. 1995; 50:316-20
7.
Densem J., and
Wald NJ. Prenat. Diagn, 1995; 15:94-5.
8. Ozturk M, Berkowitz R, Goldstein D, Bellet D, Wands JR. Am J Obstet Gynecol 1988; 158:193-8.
9.
Wald NJ, Cuckle HS, Densem JW, et at. Br Med J 1988; 297:883-7.
10.
Hay DL. BR J Obstet Gynaecol 1988; 95:1268-75.
11. Macri JN. et al. Am J Obstet Gynecol 1990; 163:1248-53.
12.
Ozturk M, et al. Endocrinology 1987; 120:499-508.
13.
Cole LA. et al. Endocrinology 1983; 113: 1176
14.
Gaspard UJ et al.
Clin Endocrinol (OXF) 1980; 13:319.
18 Free b-HCG Flow chart
| |
Standards |
Sample(s)/Controls |
| Standards
(0-5) ml Controls/Samples
ml Diluent
Buffer ml |
50 - 100 |
- 50 100 |
|
Mix
30 sec. And incubate 30 min. at 37°C Aspirate – Wash 5 x with water – Aspirate |
||
| HRP
conjugate |
150 |
150 |
|
Incubate 30 minutes at 37°C |
||
|
Substrate
solution |
100 |
100 |
|
Incubate 20 min. at RT |
||
|
Stop
solution |
100 |
100 |
|
Mix
30 sec. And read at 450 nm |
||
|